Lilly CEO Lechleiter On Drug Pricing: “The Facts Tell Us A Different Story”
This article was originally published in The Pink Sheet Daily
Executive Summary
Industry needs to do more, but be “careful and thoughtful” about responding to drug pricing criticism, Lilly CEO John Lechleiter said during the company’s third quarter call. The company’s SGLT-2 inhibitor Jardiance is already seeing a bump in prescriptions following the release of positive CV outcomes data.